

Körperliche Aktivität im Kontext von Übergewicht und Adipositas

C. Joisten

1. Timmis A et al. European Society of Cardiology: cardiovascular disease statistics 2021: Executive Summary. *Eur Heart J Qual Care Clin Outcomes* 2022; 8(4): 377–82
2. Bull FC et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. *Br J Sports Med* 2020; 54(24): 1451–62
3. Ekelund U et al. Joint associations of accelerometer measured physical activity and sedentary time with all-cause mortality: a harmonised meta-analysis in more than 44 000 middle-aged and older individuals. *Br J Sports Med* 2020; 54(24): 1499–506
4. Zhao R et al. The Dose-Response Associations of Sedentary Time with Chronic Diseases and the Risk for All-Cause Mortality Affected by Different Health Status: A Systematic Review and Meta-Analysis. *J Nutr Health Aging* 2020; 24(1): 63–70
5. Tison GH et al. Worldwide Effect of COVID-19 on Physical Activity: A Descriptive Study. *Ann Intern Med* 2020; 173(9): 767–70
6. Ekelund U et al. Do the associations of sedentary behaviour with cardiovascular disease mortality and cancer mortality differ by physical activity level? A systematic review and harmonised meta-analysis of data from 850 060 participants. *Br J Sports Med* 2019; 53(14): 886–94
7. Wharton S et al. Obesity in adults: a clinical practice guideline. *CMAJ* 2020; 192(31): E875–E891
8. Hamer O et al. Fear-related barriers to physical activity among adults with overweight and obesity: A narrative synthesis scoping review. *Obes Rev* 2021; 22(11): e13307
9. Caspersen CJ, Powell KE & Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. *Public Health Rep* 1985; 100: 126–31
10. Graf C & Ferrari N. Körperliche Aktivität, Sport und Bewegungstherapie bei (morbider) Adipositas. *Der Diabetologe* 2015; 11(6): 457–63
11. Piercy KL et al. The Physical Activity Guidelines for Americans. *JAMA* 2018; 320(19): 2020–28
12. Després JP. Physical Activity, Sedentary Behaviours, and Cardiovascular Health: When Will Cardiorespiratory Fitness Become a Vital Sign? *Can J Cardiol* 2016; 32(4): 505–13
13. Geidl W et al. Dose-response relationship between physical activity and mortality in adults with noncommunicable diseases: A systematic review and meta-analysis of cohort studies. *International Journal of Behavioral Nutrition and Physical Activity* 2020; 17: 109
14. Samitz G et al. Körperliche Aktivität und Gesamtsterblichkeit: neue Metaanalyse zur Dosis-Wirkungs-Beziehung. *Leading opinions – Kardiologie & Gefäßmedizin* 2011; 11(4): 30–33
15. Swift DL et al. The Effects of Exercise and Physical Activity on Weight Loss and Maintenance. *Prog Cardiovasc Dis* 2018; 61(2): 206–13
16. Beaulieu K et al. The Impact of Physical Activity on Food Reward: Review and Conceptual Synthesis of Evidence from Observational, Acute, and Chronic Exercise Training Studies. *Curr Obes Rep* 2020; 9(2): 63–80
17. Bellicha A et al. Effect of exercise training before and after bariatric surgery: A systematic review and meta-analysis. *Obes Rev* 2021; 22 Suppl 4(Suppl 4): e13296

18. Wewege MA et al. The effects of high-intensity interval training vs. moderate-intensity continuous training on body composition in overweight and obese adults: a systematic review and meta-analysis. *Obes Rev* 2017; 18(6): 635–46
19. Wewege MA et al. The Effect of Resistance Training in Healthy Adults on Body Fat Percentage, Fat Mass and Visceral Fat: A Systematic Review and Meta-Analysis. *Sports Med* 2022; 52(2): 287–300
20. Foss ML et al. Initial work tolerance of extremely obese patients. *Arch Phys Med Rehabil* 1975; 56(2): 63–7
21. Pedersen BK et al. Searching for the exercise factor: is IL-6 a candidate? *J Muscle Res Cell Motil* 2003; 24(2–3): 113–9
22. So B et al. Exercise-induced myokines in health and metabolic diseases. *Integrative Medicine Research* 2014; 3 (4): 172–79
23. Li H et al. Muscle-secreted granulocyte colony-stimulating factor functions as metabolic niche factor ameliorating loss of muscle stem cells in aged mice. *EMBO J* 2019; 38(24): e102154
24. Serrano AL et al. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. *Cell Metabolism* 2008; 7(1): 33–44
25. Huh JY. The role of exercise-induced myokines in regulating metabolism. *Arch Pharmacol Research* 2018; 41(1): 14–29
26. Atakan MM et al. The Role of Exercise, Diet, and Cytokines in Preventing Obesity and Improving Adipose Tissue. *Nutrients* 2021; 13(5): 1459
27. Chen W et al. Myokines mediate the cross talk between skeletal muscle and other organs. *J Cell Physiol* 2021; 236(4): 2393–412
28. Hoffmann C & Weigert C. Skeletal Muscle as an Endocrine Organ: The Role of Myokines in Exercise Adaptations. *Cold Spring Harb Perspect Med* 2017; 7(11): a029793
29. Safdar A & Tarnopolsky MA. Exosomes as Mediators of the Systemic Adaptations to Endurance Exercise. *Cold Spring Harb Perspect Med* 2018; 8(3): a029827
30. Chow LS et al. Exerkines in health, resilience and disease. *Nat Rev Endocrinol* 2022; 18(5): 273–89
31. Oppert JM et al. Exercise training in the management of overweight and obesity in adults: Synthesis of the evidence and recommendations from the European Association for the Study of Obesity Physical Activity Working Group. *Obes Rev* 2021 (a); 22 Suppl 4(Suppl 4): e13273
32. Oppert JM et al. Physical activity in management of persons with obesity. *Eur J Intern Med* 2021(b); 93: 8–12
33. Terry PC et al. Effects of music in exercise and sport: A meta-analytic review. *Psychol Bull* 2020; 146(2): 91–117
34. Pratt M. Benefits of lifestyle activity vs structured exercise. *JAMA* 1999; 281(4): 375–6
35. Hui SS et al. Effects of Tai Chi and Walking Exercises on Weight Loss, Metabolic Syndrome Parameters, and Bone Mineral Density: A Cluster Randomized Controlled Trial. *Evid Based Complement Alternat Med* 2015; 2015: 976123
36. Smith BJ et al. Encouraging physical activity--five steps for GPs. *Aust Fam Physician* 2008; 37(1–2): 24–8
37. Graf C et al. Feasibility and acceptance of exercise recommendations (10,000 steps a day) within routine German health check (Check-Up 35/GOÄ29)-study protocol. *Pilot Feasibility Stud* 2016 ; 2: 52

Medikamentöse Adipositas therapie

L. Hölzen, S. Meyhöfer

1. Aberle J et al. Adipositas und Diabetes. *Diabetologie und Stoffwechsel* 2020; 15: 139–47
2. Buse JB et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published correction appears in *Diabetes Care* 2020; 43(7): 1670]. *Diabetes Care* 2020; 43(2): 487–93
3. Deutsche Adipositas-Gesellschaft (DAG) e.V, Deutsche Diabetes Gesellschaft (DDG), Deutsche Gesellschaft für Ernährung (DGE) e.V., Deutsche Gesellschaft für Ernährungsmedizin (DGEM) e.V. (2014) Interdisziplinäre Leitlinie der Qualität S3 zur „Prävention und Therapie“ der Adipositas- Langfassung, 2. Auflage. Version 2.0. Bundesärztekammer (BÄK); Kassenärztliche Bundesvereinigung (KBV); Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)
4. Effertz T et al. The costs and consequences of obesity in Germany: a new approach from a prevalence and life-cycle perspective. *Eur J Health Econ* 2016; 17(9): 1141–58
5. Frias JP et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. *Lancet* 2018; 392(10160): 2180–93
6. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in *Lancet* 2010; 376(9741): 594] [published correction appears in *Lancet* 2010; 376(9750): 1392]. *Lancet* 2010; 376(9741): 595–605
7. Hutton B & Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. *Am J Clin Nutr* 2004; 80(6): 1461–468
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity [published online ahead of print, 2022]. *N Engl J Med* 2022; 10
9. Lautenbach A et al. Medikamentöse Adipositas therapie – Chancen und Perspektiven. *Adipositas – Ursachen, Folgeerkrankungen, Therapie* 2021; 15: 130–37
10. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 2016; 375(4): 311–22
11. Meyhöfer S et al. [Obesity –a chronic disease requiring treatment]. *Dtsch Med Wochenschr* 2022; 147: 656–62
12. OECD 2019 The Heavy Burden of Obesity: The Economics of Prevention
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. *N Engl J Med* 2015; 373: 11–22
14. Thase ME et al. A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Sustained-Release Bupropion on Blood Pressure in Individuals With Mild Untreated Hypertension. *Journal of Clinical Psychopharmacology* 2008; 28: 302–307
15. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med* 2021; 384: 989–1002
16. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. *The Lancet Diabetes & Endocrinology* 2016; 4: 913–21